Market capitalization | $207.17m |
Enterprise Value | $40.18m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.91 |
P/S ratio (TTM) P/S ratio | 30.47 |
P/B ratio (TTM) P/B ratio | 1.13 |
Revenue growth (TTM) Revenue growth | -27.94% |
Revenue (TTM) Revenue | $6.80m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
5 Analysts have issued a Molecular Partners AG - ADR forecast:
5 Analysts have issued a Molecular Partners AG - ADR forecast:
Sep '24 |
+/-
%
|
||
Revenue | 6.80 6.80 |
28%
28%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -69 -69 |
11%
11%
|
EBIT (Operating Income) EBIT | -71 -71 |
10%
10%
|
Net Profit | -71 -71 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Head office | Switzerland |
CEO | Patrick Amstutz |
Employees | 182 |
Founded | 2004 |
Website | www.molecularpartners.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.